|
Pancrelipase
resources
DRUG INFO
Pancrelipase
Drug Name:
Pancrelipase
|
|
|
Indication: For treatment of cystic fibrosis, chronic pancreatitis, pancreatic duct blockage
Pharmacology: Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism Of Action: The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Drug Category: Enzyme replacement; enzymes (44:00.00)
Brand Names/Synonyms: Pancreatic alpha-amylase precursor;PA;1,4-alpha-D- glucan glucanohydrolase; Pancrease (Ortho-McNeil); Cotazym (Organon); Ku-Zyme (Koichi); Ultrase (Axcan Scandipharm); Zymase (Organon)
Dosage Forms: TABLET
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Not Available
Chemical Formula: C5850H8902N1606O1739S49 >pancreatic triacylglycerol lipase >chymotrypsin B
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00067
CAS Registry Number: 53608-75-6
| | |
